GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PlexBio Co 6572.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

6.47

+6.41%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About PlexBio Co

Its shares trade on Taipei Exchange under the ticker 6572.TWO. It has been listed since 26 February 2016. In the fiscal year to 31 December 2025, it reported revenue of TWD 127.1m and a net loss of TWD 62.5m. At that date it held total assets of TWD 446.6m and shareholders' equity of TWD 310.4m.

PlexBio Co., Ltd. engages in research, development, manufacture, and sale of medical testing equipment and reagents. The company is headquartered in Taipei City, Taipei. The company went IPO on 2016-02-26. The firm's main products include medical testing equipment such as diversified in-vitro diagnostic (IVD) medical devices, reagents and others. The firm distributes its products within domestic markets and to overseas markets, including Taiwan, mainland China, American and other areas.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
26 Feb 2016
Website
plexbio.com ↗

Leadership

Pay as last reported

  • Mr. Dean TsaoChairman of the Board, Chief Operating Officer, General Manager, since 2009
  • Ms. Libi YeChief Financial Officer
  • Ms. Yijun LaiDirector
  • Peter C LuuDirector
  • Mr. Yasuhiro OhashiDirector
  • Mingde ChenIndependent Director
  • Mr. Te-Fung TsaoIndependent Director
  • Mr. Sonny WangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Taipei City, Taipei
  • Offers diversified in-vitro diagnostic (IVD) medical devices
  • Distributes products domestically and internationally

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share
  • No information on competitive advantages

Opportunities

  • Expanding into overseas markets including mainland China and America
  • Growing demand for medical testing equipment and reagents
  • Potential for increased sales through domestic and international distribution

Threats

  • Reliance on domestic and international markets without specified risks
  • No information on regulatory challenges or competition
  • Unspecified risks related to the health care sector

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.